What is Liquidia Technologies Inc?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.90B.
A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 15358,506 shares $10.6M | 0 |
| 3-6months | 5178,813 shares $12.9M | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 0 |